Download our whitepaper,
"Psoriasis: Clinical Endpoints, Safety Concerns, and Therapeutic Innovations"
What's Inside:
- Key FDA-Approved Pivotal Endpoints for Psoriasis Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for Psoriasis.
- Comprehensive Analysis of FDA-Approved Psoriasis Drugs.
- How Diagnostic Criteria for Psoriasis Have Evolved and Impact Research.
- Overcoming Common Pitfalls in Psoriasis Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Psoriasis
Psoriasis is a chronic and often life-altering disease characterized by the uncontrolled growth of skin cells. It is one of the most common autoimmune diseases worldwide.
In recent years, research has significantly advanced our understanding of psoriasis, uncovering its multifaceted nature involving genetic mutations, immune system dysfunction, and lifestyle and environmental factors.
This evolving knowledge has been crucial in developing current therapeutic strategies that target specific genetic mutations, utilize immune-modulating therapies, and incorporate lifestyle and environmental management.
iNGENū’s team of researchers and clinicians is dedicated to advancing Psoriasis research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by Psoriasis.
50%
of patients with moderate & Severe Psoriasis do not achieve satisfactory results with initial treatments.
If one parent has Psoriasis, their child has a 10-25% of developing Psoriasis.
If both parents have the condition, it increases to 50-70%.
Around
30%
of psoriasis patients also develop psoriatic arthritis.
Our clinical team has over
120
years of combined clinical trial experience